drugset / Trial / NCT00135395
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the anti-HIV efficacy, safety and effect of serum lipids of two boosted protease inhibitor-based HAART regimens (ARV/RTV v. LPV/RTV) in HIV-1 infected subjects who have experienced their first virologic failure while receiving a NNRTI-containing HAART regimen.
Timeline
- Start
- 2004-05
- Primary completion
- 2006-02
- Completion
- 2006-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atazanavir | Other / unclassified | 300 mg | Oral |
| Comparator | Lopinavir | Other / unclassified | 800 mg | Oral |
| Comparator | Ritonavir | Other / unclassified | 100 mg | Oral |
| Comparator | Ritonavir | Other / unclassified | 200 mg | Oral |